Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Aim: This study aimed to explore the association of immune-related adverse events (irAEs) with efficacy in advanced non-small-cell lung cancer (NSCLC). Materials 95% CI: 0.370–0.568; p < 0.001 and for OS, HR: 0.470; 95% CI: 0.410–0.539; p < 0.001), and also showed significantly higher objective response rate compared with those without irAEs (pooled OR: 0.023 95% CI: 0.009–0.590). Conclusion: This meta-analysis showed that irAEs were associated with efficacy for advanced NSCLC.